BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2020

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of operations and timing of revenue recognition

The following table presents revenues disaggregated by our business operations and timing of revenue recognition:

	Fiscal Years Ended:
	September 30,
	2020		2019
Research and development services (over-time)	$	1,128,511	$	2,975,961
Clinical laboratory testing services (point-in-time)		81,947		—
Product and authentication services (point-in-time):
Supply chain		38,577		1,438,106
Asset marking		400,491		587,012
Large scale DNA production		281,971		388,010
Total	$	1,931,497	$	5,389,089

Schedule of opening and closing contract balances

The opening and closing balances of the Company’s contract balances are as follows:

		October 1,		September 30,		$
	Balance sheet classification	2019		2020		change
Contract liabilities	Deferred revenue	$	628,993	$	511,036	$	(117,957)

Schedule of property, plant and equipment

	September 30,
	2020		2019
Computer equipment	$	90,509	$	90,509
Lab equipment		3,036,397		2,060,520
Furniture		74,781		74,781
Leasehold improvements		524,485		293,672
Total		3,726,172		2,519,482
Accumulated depreciation		2,448,517		2,293,261
Property and equipment, net	$	1,277,655	$	226,221

Schedule of anti-dilutive securities not included computation of net loss per share

	2020	2019
Warrants	1,038,919	263,592
Options	291,035	199,395
Secured convertible note	70,962	74,282
	1,400,916	573,269